Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Lilly reports full Q4 2024 financial results and provides 2025 guidance

February 10, 2025
Eli Lilly and Company has recently released its financial results for the fourth quarter of 2024 along with its guidance for the year 2025. The pharmaceutical giant reported strong growth in its revenue, exceeding expectations and showcasing its ability to adapt and succeed in the face of challenges. Despite a slight decline in weight loss diabetes drug sales, Eli Lilly managed to beat earnings estimates, reflecting the company's diverse product portfolio and commitment to innovation. Looking ahead, the company provided an optimistic outlook for 2025, projecting further growth and advancements in its pipeline of therapies. With a solid performance and promising future prospects, it could be worth considering the opinion of professionals at Stocks Prognosis for an expert forecast on the movement of Eli Lilly's stock.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYAugust 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results  ~1 min.

Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....


LLYAugust 8, 2025ELI LILLY AND COMPANY Hits Price Target Forecast with 18.31% Profit - QuantWave Achieves Success Once Again  ~2 min.

ELI LILLY AND COMPANY, one of the leading pharmaceutical companies, recently saw its stock price hitting the forecasted target with a profit of 18.31% as predicted by QuantWave on June 4, 2025....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 20.09% Profit: QuantWave Achieves Success  ~1 min.

On January 28, 2025, QuantWave, an automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was trading at 800.2 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits QuantWave Forecast, Delivering 19.57% Profit  ~1 min.

ELI LILLY AND COMPANY has achieved the price target forecast set by QuantWave, signaling a 19.57% profit for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast as QuantWave Users Gain 17.38% Profit  ~1 min.

ELI LILLY AND COMPANY stock recently achieved the price target forecast set by QuantWave, marking a significant success for users of the automated forecasting platform....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Target Forecast with 17.25% Profit: A Success Story for QuantWave  ~2 min.

ELI LILLY AND COMPANY, a leading pharmaceutical company, recently saw its stock hit the target forecast set by QuantWave, yielding a profit of 17.25%....


LLYAugust 7, 2025ELI LILLY AND COMPANY Hits Forecast Profit of 23.55%: A Success Story for QuantWave  ~2 min.

ELI LILLY AND COMPANY, a prominent player in the pharmaceutical industry, recently achieved a significant milestone by hitting a price target forecast generated by the innovative forecasting platform, QuantWave. The forecast, which indicated a short direction signal on April 17, 2025, at a price of 836.4 USD, proved to be accurate as the stock reached the predicted target price of 639.46 USD on Au...


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Target Forecast with 22.13% Profit  ~1 min.

ELI LILLY AND COMPANY stock successfully reached the forecasted target price of 639.46 $ on August 7, 2025, resulting in a profit of 22.13% for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecast Price Target, Generating 22.51% Profit for Investors  ~1 min.

ELI LILLY AND COMPANY's stock has successfully achieved the price target forecasted by QuantWave, resulting in a substantial 22.51% profit for investors....


LLYAugust 1, 2025Eli Lilly and Company Completes Acquisition of Verve Therapeutics, Advancing One-Time Treatments for High Cardiovascular Risk  ~1 min.

Eli Lilly and Company has announced the successful completion of its acquisition of Verve Therapeutics, a move that will help advance innovative one-time treatments for individuals with high cardiovascular risk. This strategic decision showcases the company's commitment to revolutionizing the healthcare industry and improving patient outcomes. Investors are eagerly watching as Eli Lilly continues ...


AMGNFebruary 26, 2025Amgen Inc. AMGN: Among the Cheap Pharmaceutical Stocks to Buy According to Analysts  ~1 min.

Analysts have identified Amgen Inc. (NASDAQ:AMGN) as one of the cheap pharmaceutical stocks to buy....


VRTXJanuary 12, 2025Vertex Pharmaceuticals Incorporated Faces Setbacks in Clinical Trials  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares experienced a slide recently due to setbacks in its clinical trials....


REGNMarch 16, 2025JIM CRAMER ENCOURAGES INVESTORS TO OWN REGENERON PHARMACEUTICALS INC.  ~2 min.

In the latest episode of Mad Money, renowned financial expert Jim Cramer expressed his bullish stance on Regeneron Pharmaceuticals Inc. (REGN)....


REGNJanuary 2, 2025Regeneron Pharmaceuticals Continues to Impress Investors with Strong Returns  ~1 min.

In the past five years, Regeneron Pharmaceuticals (NASDAQ:REGN) has delivered a solid return of 89%, making it a favorable choice for investors....


REGNFebruary 10, 2025Regeneron Pharmaceuticals Inc REGN Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... Yahoo Finance  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) recently held its Q4 2024 earnings call, highlighting strong revenue growth and positive developments in its portfolio....